Conflict of interest

From Cancer Guidelines Wiki

Competing interest declarations and management

Working Party Members were asked to declare in writing, any interests relevant to the guideline development, prior to commencement. Members were asked to update their information if they became aware of any changes to their interests.

All declarations were added to a register of interests as listed below. The register was made available to the Working Party throughout the development of the guideline, allowing members to take any potential conflicts of interest into consideration during discussions, decision making and formulation of recommendations.

If Working Party Members were identified as having a significant real or perceived conflict of interest, the Chair could decide that the member either leave the discussion whilst the specific area they were conflicted in was discussed or the member could remain present but not participate in the discussion, or decision making on the specific area where they were conflicted. There were no instances where this occurred during the development of this guideline.

The guidelines have now entered the updating phase. Guideline working party members are responsible to update their conflict of interest statements if a new interest arises. The members will receive a formal reminder to review their statements and ensure it is up-to-date prior to the yearly meetings that will be scheduled to review all updates.


Working party member Competing interest declaration
Annabel Pollard RN, BA, Grad. Dip App Psych, M Psych (Clinical) MAPS No competing interest to declare.
Caitlin Broderick To be confirmed
Associate Professor Christos Karapetis Advisory Role – Merck, Roche, BMS, Astra Zeneca, MSD

Sponsorship to attend Scientific Professional Oncology Society Meetings – Eli Lilly, Roche, Astra Zeneca, BMS, Merck Serono

Professor David Ball MB BS, MD, FRANCZR Sat on Advisory Boards for the following companies during 2010-2011:

Lilly Oncology, Boehringer- Ingelheim,Astra Zeneca and Pfizer.

Received funding to attend ASCO Chicago 2010 from Boehringer-Ingelheim.

Di Saward No competing interest to declare.
Dr Dish Gunawardana Received funding from Lilly and Roche to attend scientific meetings.

Received funding from Roche to conduct a pilot EGFR testing program in patients.

Gary Hammerschlag BSc, MBBS, FRACP To be confirmed
Associate Professor Gavin Wright MD FRACS PhD Received an Infrastructure and Educational grant to run a VATS lobectomy course provided by Covidien. Has not received financial benefit personally.
Dr Jeremy Ruben MBBCh (Hons), FCRadOnc (SA), FRANZCR, Mmed, MD (Monash) No competing interest to declare
Associate Professor Josephine Clayton MBBS PhD FRACP FAChPM No competing interest to declare.
Dr Margot Lehman MBBS FRANZCR GDP No competing interest to declare
Dr Maria Ftanou BAppSc(Hons) Dpsych Clinical No competing interest to declare.
Mary Duffy To be confirmed
Matthew Grant MBBS, FRACGP, MBioethics, DipPallMed To be confirmed
Prof Matthew Peters MD FRACP No competing interest to declare in the currency of the Working Group that are directly relevant to its work in the nominated time span.

Received honoraria for CME lectures from AstraZeneca and Boehringer Ingelheim for presentations not related to lung cancer.

Dr Melissa Moore BA BSC MBBS (Hons) FRACP PhD To be confirmed
Merlina Sulistio MBBS BMedSc FRACP (palliative medicine) To be confirmed
Professor Michael Brown MBBS PhD FRACP FRCPA Melanoma Advisory Boards for GSK, BMS, and Roche

Prostate Cancer Advisory Board for Bayer

Research support from Novartis

Travel sponsorship from Eli Lilly

Educational grant from BMS

Associate Professor Michael Michael MBBS(Hons), BSc(Hons), MD, FRACP No competing interest to declare.
Mustafa Khasraw MBChB MD MRCP FRACP Received sponsorship from Roche, Novartis and Sanofi-Aventis to attend scientific meetings.

Received a grant from Merck Serono to conduct a clinical trial.

Involved as a consultant and in an advisory capacity by Roche.

Nature of input: appraised literature regarding role of chemotherapy in stage IV lung cancer.

Dr Natasha Michael MBChB MRCP MRCGP MSC No competing interest to declare.
Assoc. Prof. Nick Pavlakis Lung Cancer Advisory Boards: Lilly, Merck-Sereno, Roche, Astra-Zeneca, Boehringer Ingelheim

Speaking Honoraria: Lilly, Roche, Merck-Sereno, Pfizer, Boehringer Ingelheim

Associate Professor Shalini Vinod MBBS MD FRANZCR No competing interest to declare.
Dr Shawgi Sukumaran To be confirmed
Dr Stephen Barnett No competing interest to declare
Dr Suzanne Kosmider Nil
Dr Tracy Smith BSc, MBBS, FRACP, Clin Dip Pall Med No competing interest to declare